Last reviewed · How we verify

Telmisartan 40mg

University of Hawaii · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Telmisartan 40mg is a Small molecule drug developed by University of Hawaii. It is currently FDA-approved. Also known as: TMS, Micardis, Pritor.

Telmisartan 40mg is a small molecule that acts as a type-1 angiotensin II receptor antagonist. It is used to treat conditions such as hypertension and essential hypertension, as well as to prevent second strokes.

At a glance

Generic nameTelmisartan 40mg
Also known asTMS, Micardis, Pritor
SponsorUniversity of Hawaii
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Telmisartan 40mg

What is Telmisartan 40mg?

Telmisartan 40mg is a Small molecule drug developed by University of Hawaii.

Who makes Telmisartan 40mg?

Telmisartan 40mg is developed and marketed by University of Hawaii (see full University of Hawaii pipeline at /company/university-of-hawaii).

Is Telmisartan 40mg also known as anything else?

Telmisartan 40mg is also known as TMS, Micardis, Pritor.

What development phase is Telmisartan 40mg in?

Telmisartan 40mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing